Prevencio and Seattle Children’s Research Institute Ink Agreement for Kawasaki Disease Diagnostic Test
Summary
With COVID-19, diagnosis for Kawasaki disease has become even more challenging and critical as the two have similar presenting symptoms, and it appears that Kawasaki Disease can be triggered by the COVID virus.” Portman added, “Without early treatment, there is a 25-30% risk of heart artery lesions which can lead to ballooning, also called aneurysms, of the heart vessels. To date, there is no diagnostic test for Kawasaki disease, and we are excited to partner with Prevencio to address this critical, unmet medical need.” Prevencio will use their long-standing, certified laboratory partner, Myriad RBM, to conduct protein measurements on the blood of children with Kawasaki disease. “We have robust experience developing highly accurate blood tests for heart disease and related complications. We are very pleased to expand use of our AI Hart platform for Kawasaki Disease and to be a part of addressing COVID-related medical issues.” About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Forward-Looking (Safe Harbor) Statement: Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties of development-stage companies.